HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

remnant-like particle cholesterol

Subscribe to New Research on remnant-like particle cholesterol

consisted of the lipoproteins remaining of the immunoaffinity gel mixture of anti-apo B-100 and A-I monoclonal antibodies coupled to Sepharose 4B

Also Known As:

RLP-C cholesterol

Networked: 29 relevant articles (0 outcomes, 2 trials/studies) for this Bio-Agent, Comments

Bio-Agent Context: Research Results

Experts

1.	Nozue, Tsuyoshi: 2 articles (02/2010 - 06/2008)
2.	Michishita, Ichiro: 2 articles (02/2010 - 06/2008)
3.	Dallinga-Thie, Geesje M: 2 articles (01/2010 - 12/2008)
4.	Hirano, Tsutomu: 2 articles (11/2008 - 06/2008)
5.	Tokuyama, K: 2 articles (09/2001 - 12/2000)
6.	Taniguchi, A: 2 articles (09/2001 - 12/2000)
7.	Sakai, M: 2 articles (09/2001 - 12/2000)
8.	Nakai, Y: 2 articles (09/2001 - 12/2000)
9.	Nagasaka, S: 2 articles (09/2001 - 12/2000)
10.	Fukushima, M: 2 articles (09/2001 - 12/2000)

Related Diseases

1.	Type 2 Diabetes Mellitus (MODY) 05/01/2000 - "Remnant-like particle cholesterol levels in Korean patients with coronary artery disease and non-insulin dependent diabetes mellitus." 05/01/2000 - "Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease." 05/01/2000 - "The purpose of this study was to investigate whether the remnant-like particle cholesterol (RLP-C) is an independent risk factor for coronary artery disease (CAD) and non-insulin dependent diabetes mellitus (NIDDM) in the Korean population and to explore the relationship between RLP-C and other biochemical markers as well as the apolipoprotein (apo) E genotypes. " 01/01/2010 - "Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets." Order ALL the reference details at left...
2.	Coronary Artery Disease (Coronary Atherosclerosis) 05/01/1998 - "RESULTS: Remnant-like particle cholesterol levels were significantly increased in men with coronary artery disease compared with controls (7.6 +/- 3.8 mg/dL versus 5.7 +/- 1.9 mg/dL, P < 0.01). " 05/01/2000 - "Remnant-like particle cholesterol levels in Korean patients with coronary artery disease and non-insulin dependent diabetes mellitus." 05/01/1998 - "SUBJECTS AND METHODS: Remnant-like particle cholesterol levels were measured in 63 normolipidemic men with coronary artery disease and 23 male controls of similar age as well as in 15 patients with type III dyslipidemia and 103 controls, using an immunoaffinity method. " 05/01/1998 - "Remnant-like particle cholesterol levels in patients with dysbetalipoproteinemia or coronary artery disease." 02/01/2000 - "Association of remnant-like particle cholesterol with coronary artery disease in patients with normal total cholesterol levels." Order ALL the reference details at left...
3.	Chronic Kidney Failure (Chronic Renal Failure) 05/01/2000 - "Thus, the aim of the present study was to compare remnant-like particle-cholesterol (RLP-C) in type 2 diabetic and ESRD patients with age- and gender-matched controls. " 05/01/2000 - "Remnant-like particle-cholesterol concentrations in patients with type 2 diabetes mellitus and end-stage renal disease." Order ALL the reference details at left...
4.	Insulin Resistance 09/01/2002 - "We investigated the relationship between insulin-resistance (IR) and remnant-like particle cholesterol (RLP-C) using 472 subjects (174 men and 298 women) randomly selected from inhabitants of two rural communities in Japan, Tanno and Sobetsu. " 09/01/2002 - "Relationship between insulin-resistance and remnant-like particle cholesterol." 12/01/2008 - "Fasting and postprandial remnant-like particle cholesterol concentrations in obese participants are associated with plasma triglycerides, insulin resistance, and body fat distribution." 10/01/2007 - "The serum amyloid A protein (SAA) was higher in SLE patients in the premenopausal state (p=0.025), while remnant like particle-cholesterol (RLP-C), the homeostasis model assessment of insulin resistance (HOMA-IR), and SAA were significantly increased in postmenopausal SLE patients (p=0.001, p<0.001 and p<0.05, respectively). " 09/01/2003 - "Multiple regression analysis showed that remnant-like particle cholesterol, fasting blood sugar and insulin resistance were independent factors for U-8-iso-PGF2 alpha concentration (p < 0.0001, p = 0.0007, p = 0.02). " Order ALL the reference details at left...
5.	Cardiovascular Diseases (Cardiovascular Disease) 11/01/2008 - "BACKGROUND: Remnant-like particle-cholesterol (RLP-C) is recognized as a risk factor for cardiovascular disease. " 01/01/2008 - "Plasma remnant-like particle-cholesterol (RLP-C) and the RBC (n-3) index are novel risk factors for cardiovascular disease. " 03/01/2005 - "A recently developed assay for quantification of remnant-like particle cholesterol has provided considerable evidence that reinforces the concept that elevated levels of plasma remnants are associated with increased cardiovascular disease in different populations and distinct patient groups. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Apolipoproteins
2.	Biological Markers (Surrogate Marker)
3.	Apolipoproteins E (ApoE)
4.	Triglycerides (Triacylglycerol)
5.	Cholesterol
6.	LDL Cholesterol
7.	HDL Cholesterol
8.	Lipoproteins (Lipoprotein)
9.	atorvastatin (Lipitor)
10.	Apolipoprotein E3

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)

blog comments powered by Disqus

TREATMENT OPTIONS
for Type 2 Diabetes Mellitus,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 673 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>